RxDoctor Payments Data

Peter Zullo, MD

Internal Medicine · Gloucester, VANPI 1043393580

Payments from drug & device makers

$2,688in general payments, 2019–2025

Across 155 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$382
  • AstraZeneca$276
  • Lilly USA, LLC$231
  • AbbVie$226
  • Pfizer$224
  • Abbott$177
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,56395%
  • Education$1255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,688 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$353,055
Medicare patients
882
Services billed
9,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide205$217,487
EliquisApixaban193$174,900
TrulicityDulaglutide87$106,041
FarxigaDapagliflozin Propanediol139$93,170
XareltoRivaroxaban57$70,361
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$36,159
JardianceEmpagliflozin23$25,024
JanumetSitagliptin Phos/Metformin Hcl22$24,872
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$24,783
EntrestoSacubitril/Valsartan28$21,200
MounjaroTirzepatide21$20,631
Breo ElliptaFluticasone/Vilanterol18$13,587
JanuviaSitagliptin Phosphate31$13,364
Lantus SolostarInsulin Glargine,hum.Rec.Anlog92$11,692
MyrbetriqMirabegron17$11,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$382$217,487205 claims
PfizerEliquis, Paxlovid$224$177,768215 claims
Lilly USA, LLCTrulicity, Mounjaro$231$126,672108 claims
AstraZenecaFarxiga$276$93,170139 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$117$74,52889 claims
Johnson & JohnsonXarelto$70$70,36157 claims
MerckJanumet, Januvia$48$38,23753 claims
Boehringer IngelheimJardiance$44$25,02423 claims
AbbVieLinzess, Synthroid$226$17,067155 claims
Astellas Pharma US IncMyrbetriq$165$11,68217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Gloucester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →